Study on Brivanib and Cetuximab for Advanced Gastrointestinal Cancer
Author Information
Author(s): Garrett C R, Siu L L, El-Khoueiry A, Buter J, Rocha-Lima C M, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten D S A
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
The study aims to determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of brivanib combined with full-dose cetuximab in patients with advanced gastrointestinal malignancies.
Conclusion
The study found that brivanib combined with cetuximab has an acceptable toxicity profile and shows promising efficacy in patients with advanced gastrointestinal cancer.
Supporting Evidence
- 6 patients (9.7%) had objective radiographic partial responses.
- The median duration of response was 9.2 months.
- The median progression-free survival was 3.9 months.
- Brivanib treatment-related adverse events were manageable.
- 14 patients died during the study, primarily due to disease progression.
Takeaway
This study tested a new cancer treatment combining two drugs, and it showed that the treatment is safe and might help some patients.
Methodology
Patients received brivanib and cetuximab, and their responses were assessed through various clinical evaluations and imaging techniques.
Limitations
The maximum tolerated dose was not reached, and the study population was heavily pretreated, which may limit the generalizability of the results.
Participant Demographics
The majority of participants were male (61%), with a median age of 60 years, primarily diagnosed with colorectal cancer.
Statistical Information
Confidence Interval
95% CI: 7.20, 16.4 months for median duration of response; 95% CI: 3.38, 5.42 months for median progression-free survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website